US 12,460,004 B2
Antibodies that bind CD277 and uses thereof
Piotr Bobrowicz, Hanover, NH (US); Paul Widboom, Lebanon, NH (US); and Michael March Schmidt, Wellesley, MA (US)
Assigned to Compass Therapeutics LLC, Brighton, MA (US)
Appl. No. 17/267,066
Filed by Compass Therapeutics LLC, Brighton, MA (US)
PCT Filed Aug. 9, 2019, PCT No. PCT/US2019/046061
§ 371(c)(1), (2) Date Feb. 9, 2021,
PCT Pub. No. WO2020/033926, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/716,551, filed on Aug. 9, 2018.
Prior Publication US 2021/0309746 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 39/3955 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 12 Claims
 
1. An isolated antibody that specifically binds human CD277, or an antigen-binding portion thereof, wherein the antibody or antigen binding portion thereof comprises heavy and light chain CDRs selected from the group consisting of:
(a) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 7-9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 10-12, respectively;
(b) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 43, 47 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 52, 58 and 62, respectively;
(c) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 45, 49 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 57, 59 and 65, respectively;
(d) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 44, 48 and 9 respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 57, 61 and 64, respectively;
(e) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 46, 50 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 56, 58 and 61, respectively;
(f) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 46, 50 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 55, 60 and 62, respectively;
(g) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 46, 50 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 54, 60 and 62, respectively;
(h) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 43, 47 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 53, 59 and 63, respectively;
(i) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 45, 49 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 53, 59 and 63, respectively;
(j) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 44, 48 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 53, 59 and 63, respectively; and
(k) heavy chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 43, 47 and 9, respectively, and light chain CDR1, CDR2 and CDR3 sequences set forth in SEQ ID NOs: 52, 58 and 62, respectively.